CORRECTION article

Front. Drug Saf. Regul., 04 December 2023

Sec. Advanced Methods in Pharmacovigilance and Pharmacoepidemiology

Volume 3 - 2023 | https://doi.org/10.3389/fdsfr.2023.1244115

Corrigendum: An industry perspective on the use of machine learning in drug and vaccine safety

  • 1. GlaxoSmithKline, Global Safety, Durham, NC, United States

  • 2. GlaxoSmithKline, Global Safety, Upper Providence, PA, United States

  • 3. GlaxoSmithKline, Global Safety, Brentford, Middlesex, United Kingdom

  • 4. London School of Hygiene and Tropical Medicine, London, United Kingdom

In the published article, there was an error in Figure 1 as published. The figure failed to include the details on the individual node references. The corrected Figure 1 and its caption appear below.

FIGURE 1

In the published article, Table 1 was mistakenly not included in the publication. The missing material appears below.

TABLE 1

NodePhaseBenefitDescription
Expected Benefits
ABefore RPAEnforcement of organizational policiesAutomation defaults to observing organizational policies in a systematic way
BIntroduction of RPAImprovement in time efficiencyReduction in time for case processing and booking
DIntroduction of RPAReduction of manual tasks and workloadReduction of repetitive, mundane, tedious manual tasks
EIntroduction of RPAImprovement in data accuracyAutomate data processing in systematic way. Decrease potential errors and mistakes in safety case review and processing
FRPA in Systematic UseDecrease in compliance riskTimelier fulfillment of compliance and audit requirements for regulatory bodies
GRPA in Systematic UseImprovement in human resource utilizationBetter utilization of staff, focus on cases which require human intervention
JRPA in Systematic UseReturn on investmentIncrease capability for high volume case processing without increasing staff
KRPA in Systematic UseIncrease in operational reliabilityAllows the organization to operate reliably, even when faced with unexpected challenges
Unexpected Benefits
CIntroduction of RPAImproved employee participationStaff is relieved from repetitive tasks and able to focus on improving overall business processes and decision making
HRPA in Systematic UseImprovement in transparency, visibility and better understanding of processesBusiness processes and business rules are judiciously executed, processes are documented and explainable to stakeholders
IRPA in Systematic UseImprovement in job satisfactionEmpower staff to focus on the most important tasks which lead to better job fulfillment

Details on the benefits of robotic process automation (RPA).

In the published article, Table 1 should now be updated as Table 2 and any associated references to Table 1 should refer to Table 2, with no changes to its legend or content.

The authors apologize for this errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

pharmacovigilance, machine learning-ML, drug safety, vaccines safety, artificial intelligence

Citation

Painter JL, Kassekert R and Bate A (2023) Corrigendum: An industry perspective on the use of machine learning in drug and vaccine safety. Front. Drug Saf. Regul. 3:1244115. doi: 10.3389/fdsfr.2023.1244115

Received

21 June 2023

Accepted

30 June 2023

Published

04 December 2023

Volume

3 - 2023

Edited by

Taxiarchis Botsis, Johns Hopkins University, United States

Reviewed by

Cristiano Matos, Escola Superior de Tecnologia da Saúde de Coimbra, ESTeSC-IPC, Portugal

Updates

Copyright

*Correspondence: Andrew Bate,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics